Silexion Therapeutics Files S-1/A, Reverse Stock Split

Ticker: SLXNW · Form: S-1/A · Filed: Mar 27, 2025 · CIK: 2022416

Sentiment: neutral

Topics: S-1/A, reverse-stock-split, corporate-action

TL;DR

Silexion (formerly Biomotion) filed an S-1/A, doing a 1-for-9 reverse split. Watch for share structure changes.

AI Summary

Silexion Therapeutics Corp. filed an S-1/A on March 27, 2025, to update its registration statement. The company, formerly known as Biomotion Sciences until May 6, 2024, is undergoing a 1-for-9 reverse share split. Their business address is 12 Abba Hillel Road, Ramat Gan, Israel.

Why It Matters

This S-1/A filing indicates ongoing regulatory activity and corporate restructuring for Silexion Therapeutics, potentially impacting its stock structure and investor relations.

Risk Assessment

Risk Level: medium — S-1/A filings often precede significant corporate actions like stock splits or offerings, which can introduce volatility and uncertainty for investors.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this S-1/A filing for Silexion Therapeutics Corp?

The S-1/A filing is an amendment to a previous registration statement, and it specifically mentions adjustments to share amounts to reflect a 1-for-9 reverse share split.

When did Silexion Therapeutics Corp. change its name from Biomotion Sciences?

The date of the name change from Biomotion Sciences to Silexion Therapeutics was May 6, 2024 (20240506).

What is the business address of Silexion Therapeutics Corp?

The business address is 12 Abba Hillel Road, Ramat Gan, L3 5250606, Israel.

What is the SIC code for Silexion Therapeutics Corp?

The Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).

What does the filing indicate about the company's share structure?

The filing explicitly states that all share amounts have been retroactively adjusted to reflect a 1-for-9 reverse share split.

Filing Details

This Form S-1/A (Form S-1/A) was filed with the SEC on March 27, 2025 regarding Silexion Therapeutics Corp (SLXNW).

View full filing on EDGAR

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing